NCT04083014View on ClinicalTrials.gov

Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 20, 2019

Primary Completion Date

March 1, 2024

Study Completion Date

March 20, 2024

Conditions

Autoimmune Hemolytic AnemiaAutoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia

Interventions

DRUG

combination of a single dose anti-CD20 antibody and bortezomib

Relapsed and refractory warm AIHA patients receive treatment of combination of a single dose anti-CD20 antibody and bortezomib twice during three months interval.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Peking Union Medical College Hospital

OTHER

NCT04083014 - Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia | Biotech Hunter | Biotech Hunter